
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2193235/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron, 2011, 72, 257-268.	8.1	3,833
2	State of play in amyotrophic lateral sclerosis genetics. Nature Neuroscience, 2014, 17, 17-23.	14.8	1,300
3	Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS. Neuron, 2010, 68, 857-864.	8.1	1,100
4	Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurology, The, 2012, 11, 323-330.	10.2	1,039
5	Amyotrophic lateral sclerosis. Nature Reviews Disease Primers, 2017, 3, 17071.	30.5	885
6	Amyotrophic lateral sclerosis. Lancet, The, 2017, 390, 2084-2098.	13.7	867
7	EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) – revised report of an EFNS task force. European Journal of Neurology, 2012, 19, 360-375.	3.3	860
8	Prognostic factors in ALS: A critical review. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 310-323.	2.1	839
9	Global Epidemiology of Amyotrophic Lateral Sclerosis: A Systematic Review of the Published Literature. Neuroepidemiology, 2013, 41, 118-130.	2.3	659
10	Incidence of amyotrophic lateral sclerosis in Europe. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 385-390.	1.9	648
11	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
12	Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 740-746.	1.9	513
13	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048.	21.4	494
14	Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurology, The, 2013, 12, 310-322.	10.2	454
15	Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurology, The, 2018, 17, 94-102.	10.2	432
16	Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nature Neuroscience, 2014, 17, 664-666.	14.8	398
17	Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain, 2005, 128, 472-476.	7.6	386
18	Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 6-11.	1.9	364

#	Article	lF	CITATIONS
19	Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurology, The, 2018, 17, 423-433.	10.2	342
20	Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurology, The, 2014, 13, 1108-1113.	10.2	302
21	Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurology, The, 2016, 15, 1182-1194.	10.2	301
22	Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 38-45.	2.1	293
23	Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nature Communications, 2016, 7, 12408.	12.8	290
24	<i>SQSTM1</i> mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology, 2012, 79, 1556-1562.	1.1	252
25	Epidemiology of ALS in Italy. Neurology, 2009, 72, 725-731.	1.1	237
26	Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 168-173.	1.9	233
27	Early symptom progression rate is related to ALS outcome. Neurology, 2002, 59, 99-103.	1.1	232
28	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	21.4	223
29	NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1037-1042.	21.4	218
30	A longitudinal study on quality of life and depression in ALS patient–caregiver couples. Neurology, 2007, 68, 923-926.	1.1	215
31	Guillain-Barre̕syndrome. Neurology, 2003, 60, 1146-1150.	1.1	214
32	Prognostic Factors in Well-Differentiated Cerebral Astrocytomas in the Adult. Neurosurgery, 1989, 24, 686-692.	1.1	207
33	Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurology, The, 2007, 6, 322-328.	10.2	206
34	Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurology, The, 2010, 9, 986-994.	10.2	205
35	Neuroimaging in amyotrophic lateral sclerosis: insights into structural and functional changes. Lancet Neurology, The, 2014, 13, 1228-1240.	10.2	201
36	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198

#	Article	IF	CITATIONS
37	Caregiver burden and patients' perception of being a burden in ALS. Neurology, 2005, 64, 1780-1782.	1.1	191
38	Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 948-950.	1.9	188
39	Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain, 2012, 135, 784-793.	7.6	182
40	Gâ€quadruplexâ€binding small molecules ameliorate <i>C9orf72</i> <scp>FTD</scp> / <scp>ALS</scp> pathology <i>inÂvitro</i> and <i>inÂvivo</i> . EMBO Molecular Medicine, 2018, 10, 22-31.	6.9	178
41	The epidemiology of ALS and the role of population-based registries. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 1150-1157.	3.8	168
42	Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 38-44.	1.9	160
43	Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology, 2014, 83, 1067-1074.	1.1	154
44	A cross sectional study on determinants of quality of life in ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1597-1601.	1.9	152
45	The role of <i>TREM2</i> R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Alzheimer's and Dementia, 2015, 11, 1407-1416.	0.8	152
46	Amyotrophic Lateral Sclerosis Outcome Measures and the Role of Albumin and Creatinine. JAMA Neurology, 2014, 71, 1134.	9.0	150
47	Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 251-259.	6.4	148
48	The multistep hypothesis of ALS revisited. Neurology, 2018, 91, e635-e642.	1.1	146
49	Extensive genetics of ALS. Neurology, 2012, 79, 1983-1989.	1.1	145
50	ALS in Italian professional soccer players: The risk is still present and could be soccer-specific. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 205-209.	2.1	144
51	Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology, 2009, 73, 1681-1685.	1.1	142
52	A Genome-Wide Association Study of Myasthenia Gravis. JAMA Neurology, 2015, 72, 396.	9.0	139
53	Histologic prognostic factors in ependymoma. Child's Nervous System, 1991, 7, 177-82.	1.1	138
54	Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 5-14.	1.7	133

#	Article	IF	CITATIONS
55	Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurology, The, 2022, 21, 465-479.	10.2	130
56	Mice with endogenous <scp>TDP</scp> â€43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. EMBO Journal, 2018, 37, .	7.8	129
57	Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1349-1353.	1.9	128
58	Two Italian kindreds with familial amyotrophic lateral sclerosis due to FUS mutation. Neurobiology of Aging, 2009, 30, 1272-1275.	3.1	128
59	Pathogenic VCP Mutations Induce Mitochondrial Uncoupling and Reduced ATP Levels. Neuron, 2013, 78, 57-64.	8.1	127
60	Neurobehavioral symptoms in ALS are negatively related to caregivers' burden and quality of life. European Journal of Neurology, 2010, 17, 1298-1303.	3.3	126
61	Evidence of multidimensionality in the ALSFRS-R Scale: a critical appraisal on its measurement properties using Rasch analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1340-1345.	1.9	126
62	Percutaneous radiological gastrostomy: a safe and effective method of nutritional tube placement in advanced ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 645-647.	1.9	124
63	The Present and the Future of Neuroimaging in Amyotrophic Lateral Sclerosis. American Journal of Neuroradiology, 2010, 31, 1769-1777.	2.4	124
64	Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurology, The, 2022, 21, 480-493.	10.2	124
65	A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. Human Molecular Genetics, 2014, 23, 2220-2231.	2.9	123
66	ALS mutant FUS proteins are recruited into stress granules in induced Pluripotent Stem Cells (iPSCs) derived motoneurons. DMM Disease Models and Mechanisms, 2015, 8, 755-66.	2.4	121
67	Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis-frontotemporal dementia phenotypes. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 754-756.	1.9	118
68	Prevalence of <i>SOD1</i> mutations in the Italian ALS population. Neurology, 2008, 70, 533-537.	1.1	118
69	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Annals of Neurology, 2019, 85, 470-481.	5.3	118
70	Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. Neurology, 1999, 53, 1123-1123.	1.1	116
71	The chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiology of Aging, 2012, 33, 209.e3-209.e8.	3.1	115
72	Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology, 2019, 93, e984-e994.	1.1	115

#	Article	IF	CITATIONS
73	Phase II/III randomized trial of TCH346 in patients with ALS. Neurology, 2007, 69, 776-784.	1.1	112
74	Mutations in the CHCHD10 gene are a common cause of familial amyotrophic lateral sclerosis. Brain, 2014, 137, e311-e311.	7.6	112
75	Amyotrophic lateral sclerosis, physical exercise, trauma and sports: Results of a population-based pilot case-control study. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 289-292.	2.1	110
76	The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 1-10.	2.1	107
77	A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. Human Molecular Genetics, 2009, 18, 1524-1532.	2.9	106
78	Specialist palliative care improves the quality of life in advanced neurodegenerative disorders: NE-PAL, a pilot randomised controlled study. BMJ Supportive and Palliative Care, 2017, 7, 164-172.	1.6	106
79	Genetic screening in sporadic ALS and FTD. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1042-1044.	1.9	105
80	Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology, 2019, 92, e1610-e1623.	1.1	105
81	Large Proportion of Amyotrophic Lateral Sclerosis Cases in Sardinia Due to a Single Founder Mutation of the TARDBP Gene. Archives of Neurology, 2011, 68, 594.	4.5	104
82	The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 844-852.	6.4	103
83	Age-related penetrance of the C9orf72 repeat expansion. Scientific Reports, 2017, 7, 2116.	3.3	102
84	Genetic counselling in ALS: facts, uncertainties and clinical suggestions. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 478-485.	1.9	99
85	ALS phenotype is influenced by age, sex, and genetics. Neurology, 2020, 94, e802-e810.	1.1	99
86	ISIS Survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. Journal of Neurology, 1999, 246, III1-III5.	3.6	98
87	Epidemiology of adult medulloblastoma. International Journal of Cancer, 1999, 80, 689-692.	5.1	97
88	Pain in amyotrophic lateral sclerosis. Lancet Neurology, The, 2017, 16, 144-157.	10.2	97
89	ALS clinical trials. Neurology, 2011, 77, 1432-1437.	1.1	96
90	Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2017, 74, 660.	9.0	96

#	Article	IF	CITATIONS
91	Factors predicting survival in ALS: a multicenter Italian study. Journal of Neurology, 2017, 264, 54-63.	3.6	96
92	Rapamycin treatment for amyotrophic lateral sclerosis. Medicine (United States), 2018, 97, e11119.	1.0	96
93	Follow-up of patients affected by manganese-induced Parkinsonism after treatment with CaNa2EDTA. NeuroToxicology, 2006, 27, 333-339.	3.0	94
94	Risk Factors in Motor Neuron Disease: A Case-Control Study. Neuroepidemiology, 1991, 10, 174-184.	2.3	93
95	Apoptosis and cell proliferation in human neuroepithelial tumors. Neuroscience Letters, 1995, 195, 81-84.	2.1	91
96	<scp><i>C9orf72</i></scp> and <scp><i>UNC13A</i></scp> are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: A genomeâ€wide metaâ€analysis. Annals of Neurology, 2014, 76, 120-133.	5.3	91
97	Lithium carbonate in amyotrophic lateral sclerosis. Neurology, 2010, 75, 619-625.	1.1	90
98	Tracheostomy in amyotrophic lateral sclerosis: a 10-year population-based study in Italy. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1141-1143.	1.9	89
99	The changing picture of amyotrophic lateral sclerosis: lessons from European registers. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 557-563.	1.9	89
100	NADPH oxidases as drug targets and biomarkers in neurodegenerative diseases: What is the evidence?. Free Radical Biology and Medicine, 2017, 112, 387-396.	2.9	88
101	Risk of cancer in patients with Guillain-Barr� syndrome (GBS). Journal of Neurology, 2004, 251, 321-326.	3.6	86
102	Valosin-containing protein (VCP) mutations in sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33, 2231.e1-2231.e6.	3.1	86
103	Prognostic Factors in Oligodendroglioma. Canadian Journal of Neurological Sciences, 1997, 24, 313-319.	O.5	85
104	Secular Trends of Amyotrophic Lateral Sclerosis. JAMA Neurology, 2017, 74, 1097.	9.0	85
105	Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. Journal of Neurology, 2015, 262, 1447-1454.	3.6	84
106	Structural brain correlates of cognitive and behavioral impairment in <scp>MND</scp> . Human Brain Mapping, 2016, 37, 1614-1626.	3.6	84
107	¹⁸ F-FDG-PET correlates of cognitive impairment in ALS. Neurology, 2016, 86, 44-49.	1.1	84
108	Ependymoma: Internal Correlations among Pathological Signs: The Anaplastic Variant. Neurosurgery, 1991, 29, 206-210.	1.1	82

#	Article	IF	CITATIONS
109	Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology, 2017, 89, 1915-1922.	1.1	82
110	Pain in amyotrophic lateral sclerosis: a populationâ€based controlled study. European Journal of Neurology, 2012, 19, 551-555.	3.3	81
111	FUS mutations in sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2011, 32, 550.e1-550.e4.	3.1	79
112	Physical activity and amyotrophic lateral sclerosis: A European populationâ€based case–control study. Annals of Neurology, 2014, 75, 708-716.	5.3	79
113	Prevalence of Parkinson's disease in northwestern italy: Comparison of tracer methodology and clinical ascertainment of cases. Movement Disorders, 1998, 13, 400-405.	3.9	78
114	C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population. Neurobiology of Aging, 2012, 33, 1848.e15-1848.e20.	3.1	76
115	Intrahemispheric and interhemispheric structural network abnormalities in PLS and ALS. Human Brain Mapping, 2014, 35, 1710-1722.	3.6	76
116	Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology, 2020, 167, 107986.	4.1	75
117	Anxiety undermines quality of life in ALS patients and caregivers. European Journal of Neurology, 2008, 15, 1231-1236.	3.3	73
118	Non-invasive ventilation in amyotrophic lateral sclerosis: a 10 year population based study. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 377-381.	1.9	73
119	Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 666-673.	1.9	73
120	Neurophysiological measures in amyotrophic lateral sclerosis: Markers of progression in clinical trials. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 17-28.	2.1	71
121	Analysis of IFT74as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurology, 2006, 6, 44.	1.8	70
122	Age of onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1. Neurobiology of Aging, 2013, 34, 357.e7-357.e19.	3.1	69
123	Genome-Wide Analysis of the Heritability of Amyotrophic Lateral Sclerosis. JAMA Neurology, 2014, 71, 1123.	9.0	69
124	Caregiver time use in ALS. Neurology, 2006, 67, 902-904.	1.1	68
125	Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 397-405.	1.7	68
126	Ubiquitin in Motor Neuron Disease. Journal of Neuropathology and Experimental Neurology, 1991, 50, 463-473.	1.7	67

#	Article	IF	CITATIONS
127	Neurobehavioral dysfunction in ALS has a negative effect on outcome and use of PEG and NIV. Neurology, 2012, 78, 1085-1089.	1.1	67
128	Repeated courses of granulocyte colonyâ€stimulating factor in amyotrophic lateral sclerosis: Clinical and biological results from a prospective multicenter study. Muscle and Nerve, 2011, 43, 189-195.	2.2	64
129	Tumor cell proliferation and apoptosis in medulloblastoma. Acta Neuropathologica, 1994, 87, 362-370.	7.7	63
130	Trauma and amyotrophic lateral sclerosis: a case–control study from a populationâ€based registry. European Journal of Neurology, 2012, 19, 1509-1517.	3.3	63
131	Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2019, 18, 155-164.	10.2	63
132	The Heterogeneity of Amyotrophic Lateral Sclerosis: A Possible Explanation of Treatment Failure. Current Medicinal Chemistry, 2007, 14, 3185-3200.	2.4	62
133	Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2017, 16, 208-216.	10.2	62
134	Accuracy of death certificate diagnosis of amyotrophic lateral sclerosis Journal of Epidemiology and Community Health, 1992, 46, 517-518.	3.7	60
135	Genetic architecture of ALS in Sardinia. Neurobiology of Aging, 2014, 35, 2882.e7-2882.e12.	3.1	60
136	UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: a population-based study. Neurobiology of Aging, 2013, 34, 357.e1-357.e5.	3.1	59
137	Genetic analysis of amyotrophic lateral sclerosis identifies contributing pathways and cell types. Science Advances, 2021, 7, .	10.3	59
138	Reliability of the El Escorial Diagnostic Criteria for Amyotrophic Lateral Sclerosis. Neuroepidemiology, 2002, 21, 265-270.	2.3	58
139	A de novo missense mutation of the FUS gene in a "true―sporadic ALS case. Neurobiology of Aging, 2011, 32, 553.e23-553.e26.	3.1	58
140	ALS/FTD phenotype in two Sardinian families carrying both <i>C9ORF72</i> and <i>TARDBP</i> mutations. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 730-733.	1.9	57
141	Association of a Locus in the <i>CAMTA1</i> Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis. JAMA Neurology, 2016, 73, 812.	9.0	57
142	Cytoplasmic accumulation of TDP-43 in circulating lymphomonocytes of ALS patients with and without TARDBP mutations. Acta Neuropathologica, 2011, 121, 611-622.	7.7	56
143	Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron, 2021, 109, 448-460.e4.	8.1	56
144	Multimodal structural MRI in the diagnosis of motor neuron diseases. NeuroImage: Clinical, 2017, 16, 240-247.	2.7	55

#	Article	IF	CITATIONS
145	TDP-43 real-time quaking induced conversion reaction optimization and detection of seeding activity in CSF of amyotrophic lateral sclerosis and frontotemporal dementia patients. Brain Communications, 2020, 2, fcaa142.	3.3	55
146	Whole-blood global DNA methylation is increased in amyotrophic lateral sclerosis independently of age of onset. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 98-105.	1.7	54
147	Proliferative activity and prognosis of low-grade astrocytomas. Journal of Neuro-Oncology, 1997, 34, 31-35.	2.9	53
148	CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. International Journal of Cancer, 2000, 88, 554-557.	5.1	53
149	Amyotrophic Lateral Sclerosis–Frontotemporal Lobar Dementia in 3 Families With p.Ala382Thr TARDBP Mutations. Archives of Neurology, 2010, 67, 1002-9.	4.5	53
150	The vascular response to tumor infiltration in malignant gliomas. Acta Neuropathologica, 1989, 77, 369-378.	7.7	52
151	<i>ATXN2</i> polyQ intermediate repeats are a modifier of ALS survival. Neurology, 2015, 84, 251-258.	1.1	52
152	Multiple sclerosis relapses: a multivariable analysis of residual disability determinants. Acta Neurologica Scandinavica, 2009, 119, 126-130.	2.1	51
153	Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis. Neuron, 2022, 110, 992-1008.e11.	8.1	51
154	Amyotrophic lateral sclerosis care in Italy: a nationwide study in neurological centers. Journal of the Neurological Sciences, 2001, 191, 145-150.	0.6	50
155	Coffee and Amyotrophic Lateral Sclerosis: A Possible Preventive Role. American Journal of Epidemiology, 2011, 174, 1002-1008.	3.4	50
156	Clinical phenotypes and radiological findings in frontotemporal dementia related to TARDBP mutations. Journal of Neurology, 2015, 262, 375-384.	3.6	50
157	Prognostic value of histologic factors in adult cerebral astrocytoma. Cancer, 1988, 61, 1386-1393.	4.1	49
158	Frontotemporal dementia with psychosis, parkinsonism, visuo-spatial dysfunction, upper motor neuron involvement associated to expansion of C9ORF72: a peculiar phenotype?. Journal of Neurology, 2012, 259, 1749-1751.	3.6	49
159	A case-control study of hormonal exposures as etiologic factors for ALS in women. Neurology, 2017, 89, 1283-1290.	1.1	48
160	Is medulloblastoma the same tumor in children and adults?. Journal of Neuro-Oncology, 1997, 35, 169-176.	2.9	46
161	Validity of hospital morbidity records for amyotrophic lateral sclerosis. Journal of Clinical Epidemiology, 2002, 55, 723-727.	5.0	46
162	The sinister side of Italian soccer. Lancet Neurology, The, 2003, 2, 656-657.	10.2	46

#	Article	IF	CITATIONS
163	Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach. Scientific Reports, 2019, 9, 690.	3.3	46
164	Association of Variants in the <i>SPTLC1</i> Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236.	9.0	46
165	Molecular Chaperones in the Pathogenesis of Amyotrophic Lateral Sclerosis: The Role of HSPB1. Human Mutation, 2016, 37, 1202-1208.	2.5	45
166	Multicentre, cross-cultural, population-based, case–control study of physical activity as risk factor for amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 797-803.	1.9	45
167	The role of preâ€morbid diabetes on developing amyotrophic lateral sclerosis. European Journal of Neurology, 2018, 25, 164-170.	3.3	45
168	Use of Multimodal Imaging and Clinical Biomarkers in Presymptomatic Carriers of <i>C9orf72</i> Repeat Expansion. JAMA Neurology, 2020, 77, 1008.	9.0	45
169	CHCH10 mutations in an Italian cohort of familial and sporadic amyotrophic lateral sclerosis patients. Neurobiology of Aging, 2015, 36, 1767.e3-1767.e6.	3.1	44
170	Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS). BMJ Open, 2019, 9, e028486.	1.9	44
171	A patient carrying a homozygous p.A382T TARDBP missense mutation shows a syndrome including ALS, extrapyramidal symptoms, and FTD. Neurobiology of Aging, 2011, 32, 2327.e1-2327.e5.	3.1	43
172	ALS patients and caregivers communication preferences and information seeking behaviour. European Journal of Neurology, 2007, 15, 071116221701004-???.	3.3	42
173	The MITOS system predicts long-term survival in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1180-1185.	1.9	42
174	Proliferating cell nuclear antigen expression in brain tumors, and its prognostic role in ependymomas: an immunohistochemical study. Acta Neuropathologica, 1993, 85, 495-502.	7.7	41
175	Risk of Guillain-Barré syndrome after 2010–2011 influenza vaccination. European Journal of Epidemiology, 2013, 28, 433-444.	5.7	41
176	Resting state functional connectivity alterations in primary lateral sclerosis. Neurobiology of Aging, 2014, 35, 916-925.	3.1	41
177	July 2017 ENCALS statement on edaravone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 471-474.	1.7	41
178	Lamotrigine reduces total postoperative analgesic requirement: A randomized double-blind, placebo-controlled pilot study. Surgery, 1997, 122, 567-570.	1.9	40
179	Amyotrophic lateral sclerosis in Sardinia, insular Italy, 1995–2009. Journal of Neurology, 2013, 260, 572-579.	3.6	40
180	TBK1 is associated with ALS and ALS-FTD in Sardinian patients. Neurobiology of Aging, 2016, 43, 180.e1-180.e5.	3.1	40

#	Article	IF	CITATIONS
181	Metabolic spatial connectivity in amyotrophic lateral sclerosis as revealed by independent component analysis. Human Brain Mapping, 2016, 37, 942-953.	3.6	40
182	Decline of cognitive and behavioral functions in amyotrophic lateral sclerosis: a longitudinal study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 373-379.	1.7	40
183	Breaking the news in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 195-201.	1.2	39
184	Understanding users and their needs. Universal Access in the Information Society, 2009, 8, 259-275.	3.0	39
185	MRI signatures of the frontotemporal lobar degeneration continuum. Human Brain Mapping, 2015, 36, 2602-2614.	3.6	39
186	Motor neuron disease in the province of Turin, Italy, 1966–1980. Journal of the Neurological Sciences, 1984, 66, 165-173.	0.6	38
187	A randomized controlled trial of recombinant interferon beta-1a in ALS. Neurology, 2000, 54, 469-469.	1.1	38
188	Bipolar affective disorder preceding frontotemporal dementia in a patient with C9ORF72 mutation: is there a genetic link between these two disorders?. Journal of Neurology, 2013, 260, 1155-1157.	3.6	38
189	The p.A382T TARDBP gene mutation in Sardinian patients affected by Parkinson's disease and other degenerative parkinsonisms. Neurogenetics, 2013, 14, 161-166.	1.4	38
190	Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Science Translational Medicine, 2022, 14, eabj0264.	12.4	38
191	Amyotrophic lateral sclerosis/frontotemporal dementia with predominant manifestations of obsessive–compulsive disorder associated to GGGGCC expansion of the c9orf72 gene. Journal of Neurology, 2012, 259, 2723-2725.	3.6	37
192	Influence of cigarette smoking on ALS outcome: a population-based study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1229-1233.	1.9	37
193	The Role of <i>APOE</i> in the Occurrence of Frontotemporal Dementia in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2016, 73, 425.	9.0	37
194	HFE H63D polymorphism is increased in patients with amyotrophic lateral sclerosis of Italian origin. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 327-327.	1.9	36
195	Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyte–colony-stimulating factor in patients with amyotrophic lateral sclerosis: results from a multicenter prospective trial. Cytotherapy, 2010, 12, 50-59.	0.7	36
196	NADPH oxidase (NOX2) activity is a modifier of survival in ALS. Journal of Neurology, 2014, 261, 2178-2183.	3.6	36
197	A longitudinal study defined circulating microRNAs as reliable biomarkers for disease prognosis and progression in ALS human patients. Cell Death Discovery, 2021, 7, 4.	4.7	36
198	Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	36

#	Article	IF	CITATIONS
199	Prognostic Factors in Adult Medulloblastoma. A Clinico-Pathologic Study. Tumori, 1995, 81, 338-346.	1.1	35
200	Comparative Analysis of C9orf72 and Sporadic Disease in a Large Multicenter ALS Population: The Effect of Male Sex on Survival of C9orf72 Positive Patients. Frontiers in Neuroscience, 2019, 13, 485.	2.8	35
201	Risk factors in the early diagnosis of ALS: European epidemiological studies. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2000, 1, S13-S18.	1.2	34
202	Activity of protein phosphatase calcineurin is decreased in sporadic and familial amyotrophic lateral sclerosispatients. Journal of Neurochemistry, 2004, 90, 1237-1242.	3.9	34
203	Structural and functional brain connectome in motor neuron diseases. Neurology, 2020, 95, e2552-e2564.	1.1	34
204	Current pathways for epidemiological research in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 33-43.	1.7	33
205	Extramotor Damage Is Associated with Cognition in Primary Lateral Sclerosis Patients. PLoS ONE, 2013, 8, e82017.	2.5	33
206	C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 281.1-281.	1.9	33
207	Interplay between spinal cord and cerebral cortex metabolism in amyotrophic lateral sclerosis. Brain, 2018, 141, 2272-2279.	7.6	33
208	The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial. Brain, 2021, 144, 2635-2647.	7.6	33
209	<i>ATXN1</i> repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization. Brain Communications, 2020, 2, fcaa064.	3.3	33
210	p27/kip1 expression in oligodendrogliomas and its possible prognostic role. Acta Neuropathologica, 1999, 98, 629-634.	7.7	32
211	Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 879-886.	1.9	32
212	Focus on the heterogeneity of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 485-495.	1.7	32
213	Eye Tracking Impact on Quality-of-Life of ALS Patients. Lecture Notes in Computer Science, 2008, , 70-77.	1.3	32
214	Involvement of Immune Response in the Pathogenesis of Amyotrophic Lateral Sclerosis: A Therapeutic Opportunity?. CNS and Neurological Disorders - Drug Targets, 2010, 9, 325-330.	1.4	32
215	Unraveling the complex interplay between genes, environment, and climate in ALS. EBioMedicine, 2022, 75, 103795.	6.1	32
216	Motor neuron disease and malignancies: results of a population-based study. Journal of Neurology, 1988, 235, 374-375.	3.6	31

#	Article	IF	CITATIONS
217	Reduced glutathione in amyotrophic lateral sclerosis: an open, crossover, randomized trial. Italian Journal of Neurological Sciences, 1998, 19, 363-366.	0.1	31
218	Validity of hospital discharge diagnoses for the assessment of the prevalence and incidence of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2001, 2, 99-104.	1.2	31
219	Mutational analysis of the VCP gene in Parkinson's disease. Neurobiology of Aging, 2012, 33, 209.e1-209.e2.	3.1	31
220	The last months of life of people with amyotrophic lateral sclerosis in mechanical invasive ventilation: A qualitative study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 499-504.	1.7	31
221	Gene-Environment-Time Interactions in Neurodegenerative Diseases: Hypotheses and Research Approaches. Annals of Neurosciences, 2018, 25, 261-267.	1.7	31
222	Patients with amyotrophic lateral sclerosis and cancer do not differ clinically from patients with sporadic amyotrophic lateral sclerosis. Journal of Neurology, 2000, 247, 778-782.	3.6	30
223	Decreased Levels of Foldase and Chaperone Proteins Are Associated with an Early-Onset Amyotrophic Lateral Sclerosis. Frontiers in Molecular Neuroscience, 2017, 10, 99.	2.9	30
224	Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12335-12338.	7.1	29
225	Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis. European Journal of Neurology, 2018, 25, 861-868.	3.3	29
226	Amyotrophic lateral sclerosis and food intake. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 267-274.	1.7	29
227	Amyotrophic lateral sclerosis mortality in Italy, 1958 to 1987. Neurology, 1993, 43, 927-927.	1.1	29
228	Motor neuron disease in the Province of Turin, Italy, 1971-1980. Acta Neurologica Scandinavica, 1983, 68, 316-327.	2.1	28
229	The prognostic role of vessel productive changes and vessel density in oligodendroglioma. Journal of Neuro-Oncology, 1999, 44, 99-107.	2.9	28
230	Amyotrophic lateral sclerosis among the migrant population to Piemonte, northwestern Italy. Journal of Neurology, 1999, 246, 175-180.	3.6	28
231	Comorbidity between CIDP and diabetes mellitus: only a matter of chance?. European Journal of Neurology, 2009, 16, 752-754.	3.3	28
232	A Multicentric Prospective Incidence Study of Guillain-Barré Syndrome in Italy. The ITANG Study. Neuroepidemiology, 2015, 45, 90-99.	2.3	27
233	A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2061-2071.	6.4	27
234	Influence of arterial hypertension, type 2 diabetes and cardiovascular risk factors on ALS outcome: a population-based study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 590-597.	1.7	27

#	Article	IF	CITATIONS
235	Telemedicine for patients with amyotrophic lateral sclerosis during COVID-19 pandemic: an Italian ALS referral center experience. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 308-311.	1.7	27
236	Cognitive screening in patients with amyotrophic lateral sclerosis in early stages. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 95-101.	2.1	26
237	Trauma and amyotrophic lateral sclerosis: a european population-based case-control study from the EURALS consortium. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 118-125.	1.7	26
238	Association between alcohol exposure and the risk of amyotrophic lateral sclerosis in the Euro-MOTOR study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 11-19.	1.9	26
239	Role of apoptosis in the prognosis of oligodendrogliomas. Neurochemistry International, 1997, 31, 245-250.	3.8	25
240	A survival analysis of 155 cases of progressive muscular atrophy. Acta Neurologica Scandinavica, 1985, 72, 407-413.	2.1	25
241	Neuropathology of Olfactory Ensheathing Cell Transplantation into the Brain of Two Amyotrophic Lateral Sclerosis (ALS) Patients. Brain Pathology, 2010, 20, 730-737.	4.1	25
242	A Distinct MR Imaging Phenotype in Amyotrophic Lateral Sclerosis: Correlation between T1 Magnetization Transfer Contrast Hyperintensity along the Corticospinal Tract and Diffusion Tensor Imaging Analysis. American Journal of Neuroradiology, 2012, 33, 733-739.	2.4	25
243	C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinson's disease complicated by psychosis or dementia in a Sardinian population. Journal of Neurology, 2015, 262, 2498-2503.	3.6	25
244	Common polymorphisms of <i>chemokine (Câ€X3â€C motif) receptor 1</i> gene modify amyotrophic lateral sclerosis outcome: A populationâ€based study. Muscle and Nerve, 2018, 57, 212-216.	2.2	25
245	Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study. Journal of Neurology, 2019, 266, 1633-1642.	3.6	25
246	Neurofilament light chain and C reactive protein explored as predictors of survival in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 436-437.	1.9	25
247	Religiousness is positively associated with quality of life of ALS caregivers. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 168-171.	2.1	24
248	Targeted Genetic Screen in Amyotrophic Lateral Sclerosis Reveals Novel Genetic Variants with Synergistic Effect on Clinical Phenotype. Frontiers in Molecular Neuroscience, 2017, 10, 370.	2.9	24
249	Rare Variant Burden Analysis within Enhancers Identifies CAV1 as an ALS Risk Gene. Cell Reports, 2020, 33, 108456.	6.4	24
250	MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genomics and Proteomics, 2009, 6, 219-27.	2.0	24
251	Phenotypic and genotypic heterogeneity of dominantly inherited amyotrophic lateral sclerosis. Acta Neurologica Scandinavica, 1987, 75, 277-282.	2.1	23
252	No evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral sclerosis. Human Molecular Genetics, 2014, 23, 1916-1922.	2.9	23

#	Article	IF	CITATIONS
253	Monocytes of patients with amyotrophic lateral sclerosis linked to gene mutations display altered TDPâ€43 subcellular distribution. Neuropathology and Applied Neurobiology, 2017, 43, 133-153.	3.2	23
254	A20 in Multiple Sclerosis and Parkinson's Disease: Clue to a Common Dysregulation of Anti-Inflammatory Pathways?. Neurotoxicity Research, 2017, 32, 1-7.	2.7	23
255	C9ORF72 hexanucleotide repeat exerts toxicity in a stable, inducible motor neuronal cell model, which is rescued by partial depletion of Pten. Human Molecular Genetics, 2017, 26, 1133-1145.	2.9	23
256	Network Analysis Identifies Disease-Specific Pathways for Parkinson's Disease. Molecular Neurobiology, 2018, 55, 370-381.	4.0	23
257	Mutational Analysis of Known ALS Genes in an Italian Population-Based Cohort. Neurology, 2021, 96, e600-e609.	1.1	23
258	Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis. Npj Genomic Medicine, 2022, 7, 8.	3.8	23
259	Ependymoma: internal correlations among pathological signs: the anaplastic variant. Neurosurgery, 1991, 29, 206-10.	1.1	23
260	Amyotrophic lateral sclerosis associated with pregnancy: report of four new cases and review of the literature. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003, 4, 45-48.	1.2	22
261	Disease penetrance in amyotrophic lateral sclerosis associated with mutations in the <i>SOD1</i> gene. Annals of Neurology, 2004, 55, 298-299.	5.3	22
262	Anaplasia Is Rare and Does Not Influence Prognosis in Adult Medulloblastoma. Journal of Neuropathology and Experimental Neurology, 2005, 64, 869-874.	1.7	22
263	Biomarkers for ALS—in search of the Promised Land. Nature Reviews Neurology, 2015, 11, 72-74.	10.1	22
264	Reconsidering the causality of TIA1 mutations in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 1-3.	1.7	22
265	Referral bias in ALS epidemiological studies. PLoS ONE, 2018, 13, e0195821.	2.5	22
266	Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis. Brain, 2022, 145, 276-284.	7.6	22
267	Early onset cerebellar ataxia with retained tendon reflexes: prevalence and gene frequency in an Italian population. Clinical Genetics, 1993, 43, 207-2011.	2.0	21
268	Amyotrophic lateral sclerosis in Piedmont (Italy): A Bayesian spatial analysis of the incident cases. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 58-65.	1.7	21
269	A de novo nonsense mutation of the FUS gene in an apparently familial amyotrophic lateral sclerosis case. Neurobiology of Aging, 2014, 35, 1513.e7-1513.e11.	3.1	21
270	Intraspinal stem cell transplantation for amyotrophic lateral sclerosis: Ready for efficacy clinical trials?. Cytotherapy, 2016, 18, 1471-1475.	0.7	21

#	Article	IF	CITATIONS
271	Incidence of amyotrophic lateral sclerosis in the province of Novara, Italy, and possible role of environmental pollution. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 284-290.	1.7	21
272	The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis. Brain, 2022, 145, 1207-1210.	7.6	21
273	Proliferating Cell Nuclear Antigen (PCNA) in Low-Grade Astrocytomas: Its Prognostic Significance. Tumori, 1994, 80, 295-300.	1.1	20
274	Fourth meeting of the European Neurological Society 25–29 June 1994 Barcelona, Spain. Journal of Neurology, 1994, 241, 1-164.	3.6	20
275	Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets. Journal of Neuro-Oncology, 2003, 61, 95-102.	2.9	20
276	The palliative care needs of people severely affected by neurodegenerative disorders: A qualitative study. Progress in Palliative Care, 2015, 23, 331-342.	1.2	20
277	Associations of Electric Shock and Extremely Low-Frequency Magnetic Field Exposure With the Risk of Amyotrophic Lateral Sclerosis. American Journal of Epidemiology, 2019, 188, 796-805.	3.4	20
278	A Dynamic Bayesian Network model for the simulation of Amyotrophic Lateral Sclerosis progression. BMC Bioinformatics, 2019, 20, 118.	2.6	20
279	Effect modification of the association between total cigarette smoking and ALS risk by intensity, duration and time-since-quitting: Euro-MOTOR. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 33-39.	1.9	20
280	TRICALS: creating a highway toward a cure. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 496-501.	1.7	20
281	Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 165-171.	1.9	20
282	ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry. Neurobiology of Aging, 2015, 36, 2906.e1-2906.e5.	3.1	19
283	Comorbidity of dementia with amyotrophic lateral sclerosis (ALS): insights from a large multicenter Italian cohort. Journal of Neurology, 2017, 264, 2224-2231.	3.6	19
284	Multicenter validation of [¹⁸ F]-FDG PET and support-vector machine discriminant analysis in automatically classifying patients with amyotrophic lateral sclerosis versus controls. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 570-577.	1.7	19
285	Identification of a pathogenic intronic KIF5A mutation in an ALS-FTD kindred. Neurology, 2020, 95, 1015-1018.	1.1	19
286	Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis. Molecular Neurodegeneration, 2021, 16, 52.	10.8	19
287	Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study. The Lancet Digital Health, 2022, 4, e359-e369.	12.3	19
288	The rare G93D mutation causes a slowly progressing lower motor neuron disease. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 35-39.	2.1	18

#	Article	IF	CITATIONS
289	Tau levels do not influence human ALS or motor neuron degeneration in the <i> SOD1 ^{G93A} </i> mouse. Neurology, 2010, 74, 1687-1693.	1.1	18
290	Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1117-1131.	6.4	18
291	Regional spreading of symptoms at diagnosis as a prognostic marker in amyotrophic lateral sclerosis: a population-based study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 291-297.	1.9	18
292	Prognostic role of slow vital capacity in amyotrophic lateral sclerosis. Journal of Neurology, 2020, 267, 1615-1621.	3.6	18
293	The links between diabetes mellitus and amyotrophic lateral sclerosis. Neurological Sciences, 2021, 42, 1377-1387.	1.9	18
294	Primary Lymphomas of the Brain: A Clinico-Pathologic Review of 37 Cases. Tumori, 1987, 73, 585-592.	1.1	17
295	Reduced cellular Ca2+ availability enhances TDP-43 cleavage by apoptotic caspases. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 725-734.	4.1	17
296	Multicentre, population-based, case–control study of particulates, combustion products and amyotrophic lateral sclerosis risk. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 854-860.	1.9	17
297	Validation of the revised classification of cognitive and behavioural impairment in ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 734-739.	1.9	17
298	Spinal cord hypermetabolism extends to skeletal muscle in amyotrophic lateral sclerosis: a computational approach to [18F]-fluorodeoxyglucose PET/CT images. EJNMMI Research, 2020, 10, 23.	2.5	17
299	Differential Neuropsychological Profile of Patients With Amyotrophic Lateral Sclerosis With and Without <i>C9orf72</i> Mutation. Neurology, 2021, 96, e141-e152.	1.1	17
300	Gompertzian Analysis of Amyotrophic Lateral Sclerosis Mortality in Italy, 1957–1987; Application to Birth Cohorts. Neuroepidemiology, 1995, 14, 269-277.	2.3	17
301	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. Brain, 2022, 145, 1757-1762.	7.6	17
302	Ubiquitinated dystrophic neurites suggest corticospinal derangement in patients with amyotrophic lateral sclerosis. Neuroscience Letters, 1994, 180, 21-24.	2.1	16
303	Basic and clinical research on amyotrophic lateral sclerosis and other motor neuron disorders in Italy: recent findings and achievements from a network of laboratories. Neurological Sciences, 2004, 25, s41-s60.	1.9	16
304	Analysis of the KIFAP3 gene in amyotrophic lateral sclerosis: a multicenter survival study. Neurobiology of Aging, 2014, 35, 2420.e13-2420.e14.	3.1	16
305	Amyotrophic Lateral Sclerosis Incidence and Previous Prescriptions of Drugs for the Nervous System. Neuroepidemiology, 2016, 47, 59-66.	2.3	16
306	Critical issues in ALS case-control studies: the case of the Euro-MOTOR study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 411-418.	1.7	16

#	Article	IF	CITATIONS
307	Exome array analysis of rare and low frequency variants in amyotrophic lateral sclerosis. Scientific Reports, 2019, 9, 5931.	3.3	16
308	Physicians' attitudes toward end-of-life decisions in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 74-81.	1.7	16
309	The NGS technology for the identification of genes associated with the ALS. A systematic review. European Journal of Clinical Investigation, 2020, 50, e13228.	3.4	16
310	Prognostic factors in ALS: A critical review. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 0, , 1-14.	2.1	16
311	Parkinson's Disease Mortality in Italy, 1951 Through 1987. Archives of Neurology, 1993, 50, 149.	4.5	15
312	Cesare Lombroso, cortical dysplasia, and epilepsy. Neurology, 2003, 61, 1412-1416.	1.1	15
313	Use of Genetic Testing in Amyotrophic Lateral Sclerosis by Neurologists. JAMA Neurology, 2017, 74, 125.	9.0	15
314	The interplay among education, brain metabolism, and cognitive impairment suggests a role of cognitive reserve in Amyotrophic Lateral Sclerosis. Neurobiology of Aging, 2021, 98, 205-213.	3.1	15
315	Amyotrophic lateral sclerosis caregiver burden and patients' quality of life during COVID-19 pandemic. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 146-148.	1.7	15
316	Cogwheel Rigidity. Archives of Neurology, 2005, 62, 828.	4.5	14
317	EFFECT OF REFERRAL BIAS ON ASSESSING SURVIVAL IN ALS. Neurology, 2007, 69, 939-940.	1.1	14
318	Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia. Journal of Neurology, 2015, 262, 2662-2667.	3.6	14
319	A mapping review of international guidance on the management and care of amyotrophic lateral sclerosis (ALS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 325-336.	1.7	14
320	Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial). BMJ Open, 2017, 7, e015434.	1.9	14
321	Clinical features and outcomes of the flail arm and flail leg and pure lower motor neuron MND variants: a multicentre Italian study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1001-1003.	1.9	14
322	Metabolic brain changes across different levels of cognitive impairment in ALS: a ¹⁸ F-FDG-PET study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 357-363.	1.9	14
323	Acute and chronic synaptic pathology in multiple sclerosis gray matter. Multiple Sclerosis Journal, 2022, 28, 369-382.	3.0	14
324	<i>SCFD1</i> expression quantitative trait loci in amyotrophic lateral sclerosis are differentially expressed. Brain Communications, 2021, 3, fcab236.	3.3	14

#	Article	IF	CITATIONS
325	Assessing and treating pain in movement disorders, amyotrophic lateral sclerosis, severe acquired brain injury, disorders of consciousness, dementia, oncology and neuroinfectivology. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. European Journal of Physical and Rehabilitation Medicine, 2016, 52, 841-854.	2.2	14
326	<scp>NADPH</scp> oxidase 2 (<scp>NOX</scp> 2) enzyme activation in patients with chronic inflammatory demyelinating polyneuropathy. European Journal of Neurology, 2016, 23, 958-963.	3.3	13
327	The role of arterial blood gas analysis (ABC) in amyotrophic lateral sclerosis respiratory monitoring. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 999-1000.	1.9	13
328	Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia. Brain, 2021, 144, 3710-3726.	7.6	13
329	Prognostic factors in adult medulloblastoma. A clinico-pathologic study. Tumori, 1995, 81, 338-46.	1.1	13
330	Mortality trends in ALS: an increasingly intricate puzzle. Lancet Neurology, The, 2005, 4, 453-454.	10.2	12
331	Amyotrophic lateral sclerosis and soccer: A different epidemiological approach strengthen the previous findings. Journal of the Neurological Sciences, 2008, 269, 187-188.	0.6	12
332	The final chapter of the ALS lithium saga. Lancet Neurology, The, 2013, 12, 324-325.	10.2	12
333	Homozygosity analysis in amyotrophic lateral sclerosis. European Journal of Human Genetics, 2013, 21, 1429-1435.	2.8	12
334	Exploiting mutual information for the imputation of static and dynamic mixed-type clinical data with an adaptive k-nearest neighbours approach. BMC Medical Informatics and Decision Making, 2020, 20, 174.	3.0	12
335	Targeted sequencing panels in Italian ALS patients support different etiologies in the ALS/FTD continuum. Journal of Neurology, 2021, 268, 3766-3776.	3.6	12
336	Update on ISIS survey: Europe, North America and South America. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2000, 1, S9-S11.	1.2	11
337	Physical fitness and amyotrophic lateral sclerosis: dangerous liaisons or common genetic pathways?. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 389-389.	1.9	11
338	A familial ALS case carrying a novel p.G147C <i>SOD1</i> heterozygous missense mutation with non-executive cognitive impairment: FigureÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1437-1439.	1.9	11
339	Novel Compound Heterozygous <i>Spatacsin</i> Mutations in a Greek Kindred with Hereditary Spastic Paraplegia SPG11 and Dementia. Neurodegenerative Diseases, 2016, 16, 373-381.	1.4	11
340	Plateaus in amyotrophic lateral sclerosis progression: results from a populationâ€based cohort. European Journal of Neurology, 2020, 27, 1397-1404.	3.3	11
341	A Study of Prognostic Factors in Motor Neuron Disease. , 1987, 209, 255-263.		11
342	Randomised controlled trial in non-invasive ventilation: what trial?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 255-256.	1.2	10

#	Article	IF	CITATIONS
343	The IVS1 +319 t>a of SOD1 gene is not an ALS causing mutation. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 45-49.	2.1	10
344	Constructional apraxia in frontotemporal dementia associated with the C9orf72 mutation: Broadening the clinical and neuropsychological phenotype. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 8-15.	1.7	10
345	Brain metabolic changes across King's stages in amyotrophic lateral sclerosis: a 18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1124-1133.	6.4	10
346	Brain metabolic correlates of apathy in amyotrophic lateral sclerosis: An 18Fâ€FDGâ€positron emission tomography stud. European Journal of Neurology, 2021, 28, 745-753.	3.3	10
347	Italian adaptation of the Beaumont Behavioral Inventory (BBI): psychometric properties and clinical usability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 81-86.	1.7	10
348	Developments in the assessment of non-motor disease progression in amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics, 2021, 21, 1419-1440.	2.8	10
349	The diagnostic value of the Italian version of the Edinburgh Cognitive and Behavioral ALS Screen (ECAS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 527-531.	1.7	10
350	Arthur Van Gehuchten takes neurology to the movies. Neurology, 2003, 61, 587-588.	1.1	9
351	Professor Camillo Negro's Neuropathological Films. Journal of the History of the Neurosciences, 2016, 25, 39-50.	0.9	9
352	Non-self-sufficiency as a primary outcome measure in ALS trials. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 77-84.	1.7	9
353	Spatial epidemiology of amyotrophic lateral sclerosis in Piedmont and Aosta Valley, Italy: a populationâ€based cluster analysis. European Journal of Neurology, 2018, 25, 756-761.	3.3	9
354	Validation of the Italian version of self-administered ALSFRS-R scale. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 151-153.	1.7	9
355	Amyotrophic lateral sclerosis with SOD1 mutations shows distinct brain metabolic changes. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2242-2250.	6.4	9
356	Clinical-anatomic study of a family with bulbo-spinal muscular atrophy in adults. Journal of the Neurological Sciences, 1986, 73, 11-22.	0.6	8
357	Conjugal amyotrophic lateral sclerosis: suggestion for the implication of environmental factors. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2001, 2, 165-166.	1.2	8
358	Early symptom progression rate is related to ALS outcome: A prospective population-based study. Neurology, 2002, 59, 2012-2013.	1.1	8
359	Treatment response and electrophysiological criteria in chronic inflammatory demyelinating polyneuropathy. European Journal of Neurology, 2006, 13, 669-670.	3.3	8
360	HFE p.H63D polymorphism does not influence ALS phenotype and survival. Neurobiology of Aging, 2015, 36, 2906.e7-2906.e11.	3.1	8

#	Article	IF	CITATIONS
361	Correlation between <i>Apolipoprotein E</i> genotype and brain metabolism in amyotrophic lateral sclerosis. European Journal of Neurology, 2019, 26, 306-312.	3.3	8
362	The Characteristics of Cognitive Impairment in ALS Patients Depend on the Lateralization of Motor Damage. Brain Sciences, 2020, 10, 650.	2.3	8
363	The transcription factor Nurr1 is up-regulated in amyotrophic lateral sclerosis patients and SOD1-G93A mice. DMM Disease Models and Mechanisms, 2020, 13, .	2.4	8
364	What is amyotrophic lateral sclerosis prevalence?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 203-208.	1.7	8
365	Arterial blood gas analysis: base excess and carbonate are predictive of noninvasive ventilation adaptation and survival in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 33-39.	1.7	8
366	Social cognition deficits in amyotrophic lateral sclerosis: A pilot crossâ€sectional populationâ€based study. European Journal of Neurology, 2022, 29, 2211-2219.	3.3	8
367	Respiratory support in a population-based ALS cohort: demographic, timing and survival determinants. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1024-1026.	1.9	8
368	Glutamate dehydrogenase (GDH) deficiency in different types of progressive hereditary cerebellar ataxia. Acta Neurologica Scandinavica, 1988, 78, 394-400.	2.1	7
369	Epidemiology of Motor Neuron Disease in Two Italian Provinces. Neuroepidemiology, 1989, 8, 79-86.	2.3	7
370	Vascular response to irradiation in malignant gliomas. Journal of Neuro-Oncology, 1990, 8, 73-84.	2.9	7
371	Motor neuron disease and optic neuropathy after acute exposure to a methanolâ€containing solvent mixture. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 188-191.	1.2	7
372	Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS. Neuron, 2011, 69, 397.	8.1	7
373	Replication of association of CHRNA4 rare variants with sporadic amyotrophic lateral sclerosis: The Italian multicentre study. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 580-584.	2.1	7
374	Occupations and amyotrophic lateral sclerosis: are jobs exposed to the general public at higher risk?. European Journal of Public Health, 2017, 27, 643-647.	0.3	7
375	NADPH oxidases 2 activation in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2018, 49, 110-111.	2.2	7
376	Analysis of the GCG repeat length in NIPA1 gene in C9orf72-mediated ALS in a large Italian ALS cohort. Neurological Sciences, 2019, 40, 2537-2540.	1.9	7
377	Lifetime sport practice and brain metabolism in Amyotrophic Lateral Sclerosis. NeuroImage: Clinical, 2020, 27, 102312.	2.7	7
378	G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial). BMJ Open, 2020, 10, e034049.	1.9	7

#	ARTICLE	IF	CITATIONS
379	The heterozygous deletion c.1509_1510delAG in exon 14 of FUS causes an aggressive childhood-onset ALS with cognitive impairment. Neurobiology of Aging, 2021, 103, 130.e1-130.e7.	3.1	7
380	Effects of intracellular calcium accumulation on proteins encoded by the major genes underlying amyotrophic lateral sclerosis. Scientific Reports, 2022, 12, 395.	3.3	7
381	Incidence of amyotrophic lateral sclerosis in Sardinia, Italy: age–sex interaction and spatial–temporal variability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 585-591.	1.7	7
382	Predicting functional impairment trajectories in amyotrophic lateral sclerosis: a probabilistic, multifactorial model of disease progression. Journal of Neurology, 2022, 269, 3858-3878.	3.6	7
383	Prognosis in amyotrophic lateral sclerosis: A population-based study. Neurology, 2003, 61, 1826-1827.	1.1	6
384	Cesare Lombroso, cortical dysplasia, and epilepsy: Keen findings and odd theories. Neurology, 2004, 63, 194-194.	1.1	6
385	Identifying potential risk factors for developing amyotrophic lateral sclerosis. Neurodegenerative Disease Management, 2011, 1, 463-471.	2.2	6
386	Monomelic amyotrophy is not always benign: A case report. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 307-308.	2.1	6
387	A novel p.E121G heterozygous missense mutation of SOD1 in an apparently sporadic ALS case with a 14-year course. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 127-128.	1.7	6
388	ATNX2 is not a regulatory gene in Italian amyotrophic lateral sclerosis patients with C9ORF72 GGGGCC expansion. Neurobiology of Aging, 2016, 39, 218.e5-218.e8.	3.1	6
389	Phenotypic variability related to C9orf72 mutation in a large Sardinian kindred. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 245-248.	1.7	6
390	A novel p.N66T mutation in exon 3 of the SOD1 gene: report of two families of ALS patients with early cognitive impairment. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 296-300.	1.7	6
391	Ceftriaxone in amyotrophic lateral sclerosis. European Journal of Neurology, 1996, 3, 295-298.	3.3	5
392	LOWER SERUM LIPID LEVELS ARE RELATED TO RESPIRATORY IMPAIRMENT IN PATIENTS WITH ALS. Neurology, 2010, 74, 2027-2028.	1.1	5
393	Amyotrophic lateral sclerosis onset after prolonged treatment with a VEGF receptors inhibitor. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 129-130.	1.7	5
394	Curable or treatable? The implications of different definitions of illness when treating patients suffering from amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 15-20.	1.7	5
395	C9ORF72 and parkinsonism: Weak link, innocent bystander, or central player in neurodegeneration?. Journal of the Neurological Sciences, 2017, 378, 49-51.	0.6	5
396	Acoustic reflex patterns in amyotrophic lateral sclerosis. European Archives of Oto-Rhino-Laryngology, 2017, 274, 679-683.	1.6	5

#	Article	IF	CITATIONS
397	Proliferating cell nuclear antigen (PCNA) in low-grade astrocytomas: its prognostic significance. Tumori, 1994, 80, 295-300.	1.1	5
398	Profiling morphologic MRI features of motor neuron disease caused by TARDBP mutations. Frontiers in Neurology, 0, 13, .	2.4	5
399	Hereditary motor and sensory neuropathies: A genetic and epidemiological study in the province of Turin, Italy. Italian Journal of Neurological Sciences, 1987, 8, 369-374.	0.1	4
400	The increase of Parkinson's disease mortality could be due to a cohort effect. Acta Neurologica Scandinavica, 1995, 92, 113-115.	2.1	4
401	Neck flexor weakness at diagnosis predicts respiratory impairment in amyotrophic lateral sclerosis. European Journal of Neurology, 2021, 28, 1181-1187.	3.3	4
402	Do ecological factors influence the clinical presentation of amyotrophic lateral sclerosis?. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1017-1019.	1.9	4
403	MDM2 overexpression is associated with short survival in adults with medulloblastoma. Neuro-Oncology, 2002, 4, 115-122.	1.2	4
404	Genome-Wide Analyses Identify KIF5A as a Novel ALS Gene. SSRN Electronic Journal, 0, , .	0.4	4
405	Brain ¹⁸ fluorodeoxyglucose-positron emission tomography changes in amyotrophic lateral sclerosis with <i>TARDBP</i> mutations. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1021-1023.	1.9	4
406	A follow-up study of 60 cases of chronic spinal muscular atrophy. Italian Journal of Neurological Sciences, 1988, 9, 47-51.	0.1	3
407	MOTONEURON DISEASE AND SOLVENT AND GLUE EXPOSURE. Lancet, The, 1989, 334, 921.	13.7	3
408	Prospective epidemiological registers: a valuable tool for uncovering ALS pathogenesis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1066-1066.	1.9	3
409	An ALS case with a novel D90N-SOD1 heterozygous missense mutation. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 393-395.	2.1	3
410	Persistent idiopathic hypoglossal nerve palsy: A motor neuron disease-mimic syndrome?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 274-276.	1.7	3
411	A novel p.Ser108LeufsTer15 SOD1 mutation leading to the formation of a premature stop codon in an apparently sporadic ALS patient: insights into the underlying pathomechanisms. Neurobiology of Aging, 2018, 72, 189.e11-189.e17.	3.1	3
412	A familial amyotrophic lateral sclerosis pedigree discordant for a novel p.Glu46Asp heterozygous OPTN variant and the p.Ala5Val heterozygous SOD1 missense mutation. Journal of Clinical Neuroscience, 2020, 75, 223-225.	1.5	3
413	Broadening the clinical spectrum of FUS mutations: a case with monomelic amyotrophy with a late progression to amyotrophic lateral sclerosis. Neurological Sciences, 2021, 42, 1207-1209.	1.9	3
414	Highlighting the clinical potential of HTT repeat expansions in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron, 2021, 109, 1947-1948.	8.1	3

#	Article	IF	CITATIONS
415	GBA variants influence cognitive status in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, , jnnp-2021-327426.	1.9	3
416	Causal associations of genetic factors with clinical progression in amyotrophic lateral sclerosis. Computer Methods and Programs in Biomedicine, 2022, 216, 106681.	4.7	3
417	Clinical trials in pediatric ALS: a TRICALS feasibility study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 481-488.	1.7	3
418	Reduced life expectancy in 40 cases of early onset cerebellar ataxia with retained tendon reflexes: a population-based study. Acta Neurologica Scandinavica, 1993, 88, 358-362.	2.1	2
419	PATHOLOGY OF THE UPPER MOTOR NEURON IN ALS. Journal of Neuropathology and Experimental Neurology, 1993, 52, 279.	1.7	2
420	Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology, 2003, 60, 1560-1561.	1.1	2
421	Apparent anticipation in SOD1 familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 452-456.	1.7	2
422	Disorders of Upper and Lower Motor Neurons. , 2015, , 261-272.		2
423	A new scale for prognostication in Parkinson disease. Neurology, 2016, 86, 982-983.	1.1	2
424	Alcohol and amyotrophic lateral sclerosis: a possible neuroprotective effect. European Journal of Neurology, 2016, 23, 221-222.	3.3	2
425	Alcohol Consumption and the Risk of Amyotrophic Lateral Sclerosis. , 2019, , 207-216.		2
426	Sleep in ALS: more than discomfort or respiratory breathing disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 5-5.	1.9	2
427	A novel splice site FUS mutation in a familial ALS case: effects on protein expression. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, , 1-9.	1.7	2
428	Untangling the knot: Lifetime physical exercise and amyotrophic lateral sclerosis. EBioMedicine, 2021, 69, 103438.	6.1	2
429	Correlations between measures of ALS respiratory function: is there an alternative to FVC?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 495-504.	1.7	2
430	Validation of the Italian version of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) administered to patients and their caregivers. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 424-429.	1.7	2
431	Post-Poliomyelitic Motor Neuron Disease. European Neurology, 1988, 28, 177-180.	1.4	1
432	IMMUNOHISTOCHEMISTRY AND IMMUNOELECTRON MICROSCOPY OF UBIQUITIN IN ALS. Journal of Neuropathology and Experimental Neurology, 1990, 49, 277.	1.7	1

#	Article	IF	CITATIONS
433	USEFULNESS OF Ki-67, CLONE MIB-1, AS A PROGNOSTIC FACTOR IN EPENDYMOMAS. Journal of Neuropathology and Experimental Neurology, 1993, 52, 324.	1.7	1
434	Degenerative neuromuscular diseases: crucial gene and cell machinery discoveries. Lancet Neurology, The, 2016, 15, 12-13.	10.2	1
435	Divining progression in Parkinson disease with a blood test. Neurology, 2019, 93, 471-472.	1.1	1
436	Atypical motor neuron disease with bent spine clinical onset and long survival carrying C9orf72 expansion. Neurological Sciences, 2021, 42, 353-355.	1.9	1
437	Tailoring patients' enrollment in ALS clinical trials: the effect of disease duration and vital capacity cutoffs. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 108-115.	1.7	1
438	Can amyotrophic lateral sclerosis progression really pause? A cohort study using the medical research council scale. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, , 1-7.	1.7	1
439	Epidemiology of adult medulloblastoma. , 1999, 80, 689.		1
440	Quality of Life and Depression in Patient-Giver Scenarios: Reference to Amyotrophic Lateral Sclerosis. , 2010, , 3511-3539.		1
441	Genetic counselling: Psychological impact and concerns. , 2018, , .		1
442	Repeated Courses of Bone Marrow-Derived Cell Mobilization Induced by Granulocyte-Colony Stimulating Factor (G-CSF) in Amyotrophic Lateral Sclerosis: Interim Analysis of a Prospective Multicenter Trial Blood, 2007, 110, 4065-4065.	1.4	1
443	Sclerosi laterale amiotrofica come modello di gestione interdisciplinare. Salute E Societa, 2015, , 173-184.	0.1	1
444	Acute, Hemorrhagic, Necrotizing Pancreatitis Associated With Riluzole Treatment in a Patient With Amyotrophic Lateral Sclerosis. American Journal of Therapeutics, 2020, Publish Ahead of Print, .	0.9	1
445	Comorbidity of Cervical Spondylogenic Myelopathy and Amyotrophic Lateral Sclerosis: When Electromyography Makes the Difference in Diagnosis. European Neurology, 2020, 83, 626-629.	1.4	1
446	Trends in Parkinson's Disease Mortality in Italy. Archives of Neurology, 1991, 48, 1010-1011.	4.5	0
447	Editorial and Guest Editorials. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2000, 1, 139-141.	1.2	0
448	Amyotrophic lateral sclerosis mimic syndrome due to a dorsal spinal cord neurofibroma. Neurological Sciences, 2010, 31, 111-113.	1.9	0
449	The quest for exogenous risk factors in ALS: Is there a place for physical activity?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 311-312.	1.7	0
450	Genetics of multiple system atrophy. Neurology, 2016, 87, 1530-1531.	1.1	0

#	Article	IF	CITATIONS
451	Systems biology analysis of the proteomic alterations in Parkinson's disease: Common and disease-specific pathways. Parkinsonism and Related Disorders, 2016, 22, e173-e174.	2.2	0
452	Stapedial Reflex: A Possible Novel Biomarker of Early Bulbar Involvement in Amyotrophic Lateral Sclerosis Patients. Audiology and Neuro-Otology, 2021, 26, 353-360.	1.3	0
453	Nature meets nurture in amyotrophic lateral sclerosis. Lancet Neurology, The, 2021, 20, 332-333.	10.2	0
454	HMSN-P associated with TFG P.PRO285LEU variant in an Italian family. Journal of the Neurological Sciences, 2021, 429, 119383.	0.6	0
455	A different cognitive and behavioral profile in ALS patients with or without C9orf72 expansion. Journal of the Neurological Sciences, 2021, 429, 117745.	0.6	0
456	Advances in the genetics of MND. Journal of the Neurological Sciences, 2021, 429, 117983.	0.6	0
457	Cortical and subcortical damage: Differences between C9orf72 ALS mutation carriers and wild-type ALS patients. Journal of the Neurological Sciences, 2021, 429, 117763.	0.6	0
458	What is amyotrophic lateral sclerosis prevalence?. Journal of the Neurological Sciences, 2021, 429, 118242.	0.6	0
459	Brain 18F-FDG-PET signature of ALS with SOD1 and TARDBP mutations. Journal of the Neurological Sciences, 2021, 429, 119396.	0.6	0
460	The role of anxiety as a prognostic factor in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2021, 429, 117743.	0.6	0
461	Validation of the Italian version of the Rasch-built overall amyotrophic lateral sclerosis disability scale (roads). Journal of the Neurological Sciences, 2021, 429, 119384.	0.6	0
462	Respiratory domain of ALSFRS-R scale increases arterial blood gas analysis' sensitivity in assessing pulmonary function in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2021, 429, 117705.	0.6	0
463	Sclerosi laterale amiotrofica e atrofie muscolari spinali. , 2009, , 427-436.		0
464	Prognostic power of the human psoas muscles FDG metabolism in amyotrophic lateral sclerosis. , 2020, , .		0
465	AlM in Amyotrophic Lateral Sclerosis. , 2022, , 1691-1703.		0
466	ISIS Survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. Journal of Neurology, 1999, 246, s001-s005.	3.6	0
467	Amyotrophic lateral sclerosis associated with pregnancy: report of four new cases and review of the literature. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003, 4, 45-48.	1.2	0